Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


International Conference and Expo on Dermatopathology and Skin Care

Toronto, Canada

Dr. Anahí Pontón de Katz

Dr. Anahí Pontón de Katz

Hospital Metropolitano, Quito, Ecuador

Title: 8 years' experience of Mohs micrographic surgery in an Ecuador Center


Biography: Dr. Anahí Pontón de Katz



The non melanoma skin cancer accounts for 95% of all  skin cancer. Although various treatment modalities are available, the most frequently used option  is surgical excision. Here, we evaluate the efficacy of Mohs micrographic surgery for the treatment of non melanoma skin cancer.

Material and  methods

A retrospective review of all cases of non melanoma carcinoma treated with Mohs micrographic surgery between July 2010 and May 2018 was performed using patient records from Hospital Metropolitano of Quito, the unique Mohs micrographic surgery Center of Ecuador.


A total of 169 non melanoma skin cancer cases treated with Mohs micrographic surgery were identified; 50.5% were in women and 49.5% in men. The mean age of the patients was 70.7 years (range 35 –100 years). The histologic type of the tumor was  basocelular carcinoma in 80.7% of cases and in 97% of cases the tumor was located on the head or neck. Ten percent of the tumors were recurrent following previous treatment. A mean of 1.57 Mohs stages were used, with a mean of  2.05 sections. The mean size of the initial defect was 0.75cm2 and the mean final defect was 2.05cm2. The ratio of  intial tumor size to final defect was estimated at 1.02cm2. Over a mean follow-up of  39 months, there were 2 cases of tumor recurrence (1.1%).


In our experience, Mohs micrographic surgery is effective for the treatment of high-risk non melanoma skin carcinoma.